NCT02648438 - A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2016

Primary Completion Date

June 1, 2016

Study Completion Date

June 1, 2016

Conditions

AsthmaChronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

AZD7594 Solution for infusion (150 μg intravenous formulation)

Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV

DRUG

AZD7594 Oral suspension (1200 μg oral formulation)

0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral

DRUG

AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)

Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)

DRUG

AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)

Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)

DRUG

AZD7594 Pressurized inhalation suspension (400 μg) by pMDI

Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg

Trial Locations (1)

Research Site, Baltimore